Research programme: oral nucleoside analogues - Pharmasset

Drug Profile

Research programme: oral nucleoside analogues - Pharmasset

Alternative Names: Nucleos(t)ide analogue polymerase inhibitors - Pharmasset; PSI-352666; PSI-352879; PSI-353661; PSI-6206; PSI-6206 monophosphate; PSI-6206 phosphate; PSI-6206 triphosphate; PSI-661; PSI-879

Latest Information Update: 02 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmasset
  • Class Nucleosides; Nucleotides; Purine nucleotides; Pyrimidine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C; HIV infections

Most Recent Events

  • 02 Feb 2012 No development reported - Preclinical for Hepatitis C in USA (PO)
  • 02 Feb 2012 No development reported for HIV infections in USA (PO)
  • 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top